Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment

The rate at which parasitemia declines in a host after treatment with an antimalarial drug is a major metric for assessment of antimalarial drug activity in preclinical models and in early clinical trials. However, this metric does not distinguish between viable and nonviable parasites. Thus, enumer...

Descripción completa

Detalles Bibliográficos
Autores principales: Radohery, Georges F. R., Walz, Annabelle, Gumpp, Christin, Cherkaoui-Rbati, Mohammed H., Gobeau, Nathalie, Gower, Jeremy, Davenport, Miles P., Rottmann, Matthias, McCarthy, James S., Möhrle, Jörg J., Rebelo, Maria, Demarta-Gatsi, Claudia, Khoury, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295577/
https://www.ncbi.nlm.nih.gov/pubmed/35727057
http://dx.doi.org/10.1128/aac.00114-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295577/
https://www.ncbi.nlm.nih.gov/pubmed/35727057
http://dx.doi.org/10.1128/aac.00114-22

Ejemplares similares